Cytokinetics (CYTK) Cash from Operations (2016 - 2024)
Historic Cash from Operations for Cytokinetics (CYTK) over the last 15 years, with Q4 2024 value amounting to -$65.6 million.
- Cytokinetics' Cash from Operations rose 1142.27% to -$65.6 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$395.9 million, marking a year-over-year increase of 444.88%. This contributed to the annual value of -$395.9 million for FY2024, which is 444.88% up from last year.
- Per Cytokinetics' latest filing, its Cash from Operations stood at -$65.6 million for Q4 2024, which was up 1142.27% from -$101.5 million recorded in Q3 2024.
- Cytokinetics' 5-year Cash from Operations high stood at $52.2 million for Q4 2020, and its period low was -$129.5 million during Q1 2024.
- In the last 5 years, Cytokinetics' Cash from Operations had a median value of -$69.8 million in 2023 and averaged -$62.2 million.
- Its Cash from Operations has fluctuated over the past 5 years, first surged by 37368.14% in 2020, then plummeted by 36985.45% in 2021.
- Over the past 5 years, Cytokinetics' Cash from Operations (Quarter) stood at $52.2 million in 2020, then tumbled by 185.79% to -$44.7 million in 2021, then tumbled by 119.48% to -$98.2 million in 2022, then rose by 24.6% to -$74.0 million in 2023, then increased by 11.42% to -$65.6 million in 2024.
- Its last three reported values are -$65.6 million in Q4 2024, -$101.5 million for Q3 2024, and -$99.3 million during Q2 2024.